Conditions: Breast Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 90
Healthy volunteers: no

Brief summary:
This single-arm study assessed the efficacy and safety of first-line treatment with Avastin (bevacizumab) in combination with taxane-based chemotherapy (paclitaxel and gemcitabine) in patients with HER-2 negative breast cancer. Patients received Avastin 10 mg/kg iv, paclitaxel 150 mg/m\^2 iv, and gemcitabine 200 mg/m\^2 iv on Day 1 and Day 15 of each 4-week treatment cycle until disease progression, death, or withdrawal of consent.

Detailed description:

Arms:
arm 1: Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m\^2 IV, and gemcitabine 2000 mg/m\^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.

Interventions: intervention 1: Bevacizumab intervention 2: Paclitaxel intervention 3: Gemcitabine
Intervention descriptions: intervention 1: Bevacizumab was supplied as a sterile liquid in glass vials. intervention 2: Paclitaxel was supplied as a sterile liquid in glass vials. intervention 3: Gemcitabine was supplied as a sterile liquid in glass vials.

Protocol document: